Impact of type 2 diabetes on adenoma detection in screening colonoscopies performed in disparate populations

Table 3 Comparison of patient characteristics between type 2 diabetes mellitus and nondiabetic patients at an urban public hospital

Variables	T2DM, n = 529	NoDM, n = 1077	P value
Age (yr) median ± IQR	58 ± 11	55 ± 10	< 0.0001
Male sex, n (%)	189 (35.7)	379 (35.2)	0.8627
Race, n (%)			0.8741
Black/AA	493 (93.2)	995 (92.4)
Non-Hispanic White/EA	2 (0.4)	3 (0.3)
Asian	2 (0.4)	6 (0.6)
Other	32 (6.0)	73 (6.8)
Hispanic ethnicity, n (%)	26 (5.6)	43 (4.5)	0.4329
BMI (kg/m2), median ± IQR	29.5 ± 7.5	28.3 ± 7.5	< 0.0001
Smoking, n (%)			0.0494
Current	20 (3.9)	75 (7.1)
Past	20 (3.9)	39 (3.7)
Never	471 (92.2)	946 (89.2)
Aspirin use, n (%)	135 (25.5)	130 (12.1)	< 0.0001
HIV status, n (%)	26 (4.9)	64 (5.9)	0.4245
Fellow participation, n (%)	119 (22.5)	263 (24.4)	0.4125
Quality of colonoscopic prep			0.3346
Good	511 (96.6)	1050 (97.5)
Fair	18 (3.4)	27 (2.5)
Insurance, n (%)			0.2072
Commercial	85 (16.1)	180 (16.7)
Medicare	20 (3.8)	23 (2.1)
Medicaid	326 (61.6)	652 (60.5)
Self-pay	98 (18.5)	222 (20.6)

T2DM: Type 2 diabetes mellitus; AA: African ancestry; EA: European ancestry; IQR: Interquartile range; BMI: Body mass index; NoDM: Nondiabetics; HIV: Human immunodeficiency virus.